Dr. Frank Young - Braeburn Pharmaceuticals
And finally this week, Braeburn Pharmaceuticals has appointed former FDA Commissioner Dr. Frank Young as Executive Vice President, Clinical and Regulatory Affairs, as it awaits approval of its first product Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction.
Young, who served as Commissioner of the U.S. Food and Drug Administration (FDA) from 1984 to 1989, “brings extensive knowledge and experience to the Braeburn team at this important time for our company,” said Braeburn’s COO Behshad Sheldon.
“As we continue to work collaboratively with FDA, we are confident that Dr. Young’s counsel will help us navigate the process and expedite the evaluation of Probuphine to make this novel treatment option available to patients suffering from opioid addiction.”
